To participate in the PRECEDENT Study, the participant must be at least 18 years of age and have platinum-resistant ovarian cancer.
Potentially eligible if all of the following are true:
- Participant has ovarian cancer, fallopian tube cancer or primary peritoneal cancer.
- Participant’s disease progressed within 6 months of the first or second treatment with a platinum based chemotherapy drug (cisplatin or carboplatin).
- Participant has either radiographic evidence of measurable disease (i.e., at least one measurable target lesion) or a CA-125 of greater than 2 times the upper limit of normal, and adequate bone marrow, hepatic and renal function.
- Participant has not been previously treated with Doxil®.
Not eligible if any of the following are true:
- Individual diagnosed with tumor of low malignant potential.
- Individual had prior exposure to Doxil®, other anthracyclines, folate receptor-targeted therapy (e.g. EC145, EC0225, EC0489, farletuzumab), or mouse antibodies.
- Individual had a recent history (6 weeks or less) of peritonitis or abdominal surgery, prior abdominal or pelvic radiation therapy, radiation therapy to greater than 10% of the bone marrow, or prior radiation therapy within the past 3 years to the breast/sternum, dermal lesions, head or neck.